{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:36:13Z","timestamp":1793478973123,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,9,20]]},"abstract":"\n Importance<\/jats:title>\n Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind, parallel-group, placebo-controlled randomized clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from February 2017 to October 2019. Final follow-up occurred in November 2020. Inclusion criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the C-reactive protein level [CRP PMR-AS] &gt;10) and prednisone dose greater than or equal to 10 mg per day.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomly assigned to receive intravenous tocilizumab (8 mg\/kg; n\u2009=\u200951) or placebo (n\u2009=\u200950) every 4 weeks for 24 weeks, combined with predefined standardized tapering of oral prednisone.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary efficacy end point was CRP PMR-AS less than 10 (range, 0-100; higher values indicate greater activity; no minimal clinically important difference defined) combined with either prednisone dose less than or equal to 5 mg per day or a decrease in prednisone dose greater than or equal to 10 mg from baseline at week 24. There were 11 secondary outcomes assessed at week 24 included in this report, including disease activity (measured by CRP PMR-AS) and the proportion of patients no longer taking prednisone.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 101 randomized patients (mean age, 67.2 years; 68 [67.3%] women), 100 (99%) received at least 1 infusion and 100 completed the trial. The primary end point was achieved in 67.3% of patients in the tocilizumab group and 31.4% of patients in the placebo group (adjusted difference, 36.0% [95% CI, 19.4%-52.6%]; adjusted relative risk, 2.3 [95% CI, 1.5-3.6];\n P<\/jats:italic>\n \u2009&lt;\u2009.001). Of 11 reported secondary end points at 24 weeks, 7 showed significant differences favoring tocilizumab, including mean CRP PMR-AS score (7.5 [95% CI, 5.4-9.6] vs 14.9 [95% CI, 11.4-18.4]; adjusted difference, \u22127.5 [95% CI, \u221211.2 to \u22123.8];\n P<\/jats:italic>\n \u2009&lt;\u2009.001) and the percentage of patients no longer receiving prednisone (49.0% vs 19.6%; adjusted difference, 29.3% [95% CI, 18.9%-39.7%]; adjusted relative risk, 2.5 [95% CI, 1.8-3.5];\n P<\/jats:italic>\n \u2009&lt;\u2009.001). The most frequent adverse events were infections, experienced by 23 patients (46.9%) in the tocilizumab group and 20 (39.2%) in the placebo group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with active polymyalgia rheumatica despite prednisone therapy, tocilizumab, compared with placebo, resulted in a significantly greater percentage of patients with a CRP PMR-AS less than 10 with reduced prednisone requirements at week 24. Further research is needed to confirm efficacy and to determine the balance of potential benefits and harms.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02908217<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2022.15459","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:05:37Z","timestamp":1663671937000},"page":"1053","source":"Crossref","is-referenced-by-count":122,"title":["Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy"],"prefix":"10.1001","volume":"328","author":[{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"first","affiliation":[{"name":"Rheumatology Department, Brest University Hospital, Brest, France"},{"name":"INSERM 1227, Brest University, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Carvajal-Alegria","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Brest University Hospital, Brest, France"},{"name":"INSERM 1227, Brest University, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Dernis","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Community Hospital, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Bordeaux University Hospital and Bordeaux University, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Bordeaux University Hospital and Bordeaux University, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Besan\u00e7on Regional University Hospital and Bourgogne Franche-Comt\u00e9 University, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Toussirot","sequence":"additional","affiliation":[{"name":"INSERM CIC-1431 Clinical Investigations Center, Besan\u00e7on University Hospital Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleth","family":"Perdriger","sequence":"additional","affiliation":[{"name":"Rennes 1 University, School of Medicine, South Hospital, Rheumatology Department, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Strasbourg University Hospitals, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Strasbourg University Hospitals, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Jean","family":"Fautrel","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 \u2013 Assistance Publique H\u00f4pitaux de Paris, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Rheumatology Department, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chiche","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, European Hospital, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Hilliquin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Le Henaff","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital, Morlaix, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Dervieux","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital, Mulhouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Direz","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Community Hospital, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Chary-Valckenaere","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nancy University Hospital, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Brest University Hospital, Brest, France"},{"name":"INSERM 1227, Brest University, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Guellec","sequence":"additional","affiliation":[{"name":"Clinical Investigations Centre (CIC) 1412, National Health and Medical Research Institute (INSERM), Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Marhadour","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Brest University Hospital, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nowak","sequence":"additional","affiliation":[{"name":"Public Agency for Clinical Research and Innovation (DRCI), Brest University Hospital, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Brest University Hospital, Brest, France"},{"name":"INSERM 1227, Brest University, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"jpc220004r1","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review.","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"jpc220004r2","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative.","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"jpc220004r3","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica.","volume":"32","author":"Kremers","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"jpc220004r4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study.","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"jpc220004r5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"11","key":"jpc220004r6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial.","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"jpc220004r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102670","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle.","volume":"19","author":"Carvajal Alegria","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"jpc220004r8","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/art.v66.7","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.","volume":"66","author":"van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"jpc220004r9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis.","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"jpc220004r10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"jpc220004r11","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica.","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"jpc220004r12","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/apl.v22.12","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study.","volume":"22","author":"Chino","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"jpc220004r13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209607","article-title":"Tocilizumab in recent polymyalgia rheumatica: how can we manage the interleukin-6 blockage?","volume":"75","author":"Devauchelle","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"jpc220004r14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","article-title":"Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.","volume":"57","author":"Devauchelle-Pensec","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"jpc220004r15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.","volume":"97","author":"Chuang","year":"1982","journal-title":"Ann Intern Med"},{"issue":"2","key":"jpc220004r16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3899\/jrheum.110866","article-title":"Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice.","volume":"39","author":"Cleuziou","year":"2012","journal-title":"J Rheumatol"},{"issue":"10","key":"jpc220004r17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica.","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"jpc220004r18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/ard.2002.002618","article-title":"EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).","volume":"62","author":"Leeb","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jpc220004r19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3899\/jrheum.200248","article-title":"Outcomes measured in polymyalgia rheumatica and measurement properties of instruments considered for the OMERACT core outcome set: a systematic review.","volume":"48","author":"Twohig","year":"2021","journal-title":"J Rheumatol"},{"issue":"9","key":"jpc220004r20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3899\/jrheum.190575","article-title":"Feasibility and face validity of outcome measures for use in future studies of polymyalgia rheumatica: an OMERACT study.","volume":"47","author":"Yates","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"jpc220004r21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios.","volume":"57","author":"Binard","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"jpc220004r22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Performance of the polymyalgia rheumatica activity score for diagnosing disease flares.","volume":"59","author":"Binard","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"jpc220004r23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2008.088526","article-title":"Validity of the polymyalgia rheumatica activity score in primary care practice.","volume":"68","author":"Binard","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"jpc220004r24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"issue":"3","key":"jpc220004r25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/ard.2010.133850","article-title":"Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.","volume":"70","author":"Dejaco","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"jpc220004r26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"jpc220004r27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"jpc220004r28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1197\/S1069-6563(03)00372-5","article-title":"Clinically important change in the visual analog scale after adequate pain control.","volume":"10","author":"Lee","year":"2003","journal-title":"Acad Emerg Med"},{"issue":"9617","key":"jpc220004r29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"jpc220004r30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative.","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"jpc220004r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105117","article-title":"Tocilizumab controls bone turnover in early polymyalgia rheumatica.","volume":"88","author":"Carvajal Alegria","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"8","key":"jpc220004r32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/rheumatology\/kex169","article-title":"Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica.","volume":"56","author":"Carvajal Alegria","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"jpc220004r33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-017-1499-2","article-title":"Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab.","volume":"20","author":"Huwart","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"jpc220004r34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00259-015-3287-z","article-title":"Value of (18)F-FDG PET\/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.","volume":"43","author":"Palard-Novello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"jpc220004r35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"jpc220004r36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40744-021-00299-8","article-title":"Inflammatory markers are quickly improved by tocilizumab in early polymyalgia rheumatica and might predict early response to interleukin-6 blockade.","volume":"8","author":"Carvajal Alegria","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"3","key":"jpc220004r37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2796378\/jama_devauchellepensec_2022_pc_220004_1663338133.12772.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:05:42Z","timestamp":1663671942000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2796378"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,9,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.15459","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}